Teva Pharmaceutical Industries Limited


$13.05 USD

$0.05 (0.38%)

Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
Year High
Year Low
Payout Ratio
Current Ratio

Industry, Sector & symbol

Stock Exchange New York Stock Exchange
CEO Mr. Richard D. Francis
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Current Symbol TEVA
CUSIP 881624209
CIK 0000818686
Phone 972 3 914 8213
Currency USD
Employees 35001
Country IL


Debt-to-Equity Ratio 2.48
Payout Ratio 0.00
Current Ratio 1.02
Quick Ratio 0.54
Cash Ratio 0.26

Sales & Book Value

Annual Sales $15.84B
Price / Sales 0.92
Cash Flow 0.75
Price / Cash Flow 17.39
Price / Book 1.80

Price Target and Rating

Average Stock Price Forecast $11.50
High Stock Price Forecast $19.00
Low Stock Price Forecast $10.00
Forecast Upside/Downside 13.48%
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 8 Analysts


EPS (Most Recent Fiscal Year) $-0.5
Trailing P/E Ratio -27.76
PEG Ratio -0.36
P/E Growth -0.36
Net Income $-559M
Net Margin -3.33%
Pretax Margin -3.72%
Return on Equity -7.03%
Return on Assets -1.21%

Financials Score

AltmanZ Score 0.82
Piotroski Score 5.00
Working Capital 238M
Total Assets 43.48B
Ebit 2.7B
Market Cap 14.48B
Total Liabilities 35.35B

Poll Results

About Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and A ... USTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharm to stay as unified generics, branded drugmaker, CEO says

2024-02-20 04:45:31

Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard Francis said on Tuesday.

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

2024-02-01 12:56:04

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Teva's CEO talks Q4 earnings and how he is implementing his 'pivot to growth' strategy

2024-01-31 16:20:07

Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy.

Teva Pharma CEO Richard Francis on Q4 earnings

2024-01-31 12:32:20

Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.

Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-01-31 11:31:07

Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Frequently Asked Questions

What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?

Teva Pharmaceutical Industries Limited(NYSE:TEVA) stock price is $13.05 in the last trading session. During the trading session, TEVA stock reached the peak price of $13.35 while $7.09 was the lowest point it dropped to. The percentage change in TEVA stock occurred in the recent session was 0.38% while the dollar amount for the price change in TEVA stock was $0.05.

TEVA's industry and sector of operation?

The NYSE listed TEVA is part of Drug Manufacturers—Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of TEVA?

Mr. Kevin C. Mannix | Senior Vice President of Investor Relations
Mr. Richard D. Francis | President, Chief Executive Officer & Director
Ms. Vikki Conway | Acting Head of Global Human Resources
Dov Bergwerk | Acting Chief Legal Officer & Corporate Secretary
Mr. Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer

How many employees does TEVA have?

Number of TEVA employees currently stands at 35001. TEVA operates from 124 Dvora Hanevi’a Street, Tel Aviv, None 6944020, IL.

Link for TEVA official website?

Official Website of TEVA is:

How do I contact TEVA?

TEVA could be contacted at phone #972 3 914 8213 and can also be accessed through its website. TEVA operates from 124 Dvora Hanevi’a Street, Tel Aviv, None 6944020, IL.

How many shares of TEVA are traded daily?

The average number of TEVA shares traded daily for last 3 months was 10.44M.

What is the market cap of TEVA currently?

The market value of TEVA currently stands at $14.63B with its latest stock price at $13.05